AB Science is pleased to announce that Health Canada has deemed the request for reconsideration of masitinib in amyotrophic lateral sclerosis to be admissible.This reconsideration process will.
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM. | April 12, 2023